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Background: The Cancer Testis Antigens (CTAs) are a group of genes that are highly expressed in the normal testis
and several types of cancer. Due to their restricted expression in normal adult tissues, CTAs have been attractive
targets for immunotherapy and biomarker development. In this work, we discovered that Centrin 1 (CETN1) which
is found in the centrosome of all eukaryotes, may be a member of this group and is highly expressed in prostate
and pancreatic cancer. Three members of the centrin family of calcium binding proteins (CETN) are localized to the
centrosome in all eukaryotes with CDC31 being the sole yeast homolog. CETN1 is a retrogene that probably arose
from a retrotransposition of CETN2, an X-linked gene. A previous mouse study shows that CETN1 is expressed solely
in the testis, while CETN2 is expressed in all organs.
Results: In this work, we show that CETN1 is a new member of the growing group of CTAs. Through the mining of
publicly available microarray data, we discovered that human CETN1 expression but not CETN2 or CETN3 is
restricted to the testis. In fact, CETN1 is actually down-regulated in testicular malignancies compared to normal
testis. Using q-PCR, CETN1 expression is shown to be highly up-regulated in cancer of the prostate and in
pancreatic xenografts. Unexpectedly however, CETN1 expression was virtually absent in various cell lines until they
were treated with the DNA demethylation agent 5’AZA-2’Deoxycytidine (AZA) but showed no increased expression
upon incubation with Histone deacetylase inhibitor Trichostatin-A (TSA) alone. Additionally, like most CTAs, CETN1
appears to be an intrinsically disordered protein which implies that it may occupy a hub position in key protein
interaction networks in cancer. Neither CETN1 nor CETN2 could compensate for loss of CDC31 expression in yeast
which is analogous to published data for CETN3.
Conclusions: This work suggests that CETN1 is a novel CTA with expression in cancer of the prostate and pancreas.
In cell lines, the expression is probably regulated by promoter methylation, while the method of regulation in
normal adult tissues remains unknown.
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Centrins are calcium-binding phosphoproteins with four
Ca2+-binding EF-hand domains that are localized to the
centrosome of all eukaryotes [1]. Centrosomes are the
main Microtubule-Organizing Center (MTOC), which
has an essential role in mitosis/meiosis and has shown
to be amplified in cancer [2,3]. Within a centrosome, the* Correspondence: smooney4@jhmi.edu
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reproduction in any medium, provided the orcentrioles play a pivotal role as organizers of the
pericentriolar material that is primarily responsible for
coordinating the nucleation of microtubule assembly [4].
As critical constituents of the centriole, centrins play
an important role in cytokinesis and cell cycle progres-
sion [5]. For example, gene disruption experiments in
yeast demonstrate that centrin (CDC31) is essential for
cell viability [6]. Further, in yeast and other eukaryotes,
deletions and mutations in the calcium binding domains
can cause an incomplete basal body maintenance, separ-
ation, and orientation, important in ciliary function [7].
Finally, siRNA-mediated silencing of CETN2 in HeLa. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cell death [4].
Emerging evidence also suggests that human CETN2
plays a regulatory role in the DNA damage recognition
during the first steps of nucleotide excision repair by
binding to the xeroderma pigmentosum group C (XPC)
protein [8]. CETN2 promotes DNA binding by XPC and
increases the specificity of the heterotrimer for damaged
DNA [9,10]. Finally, data from yeast and Xenopus indi-
cate additional functions of the centrins that include
mRNA transport from the nucleus [11,12]. Considered
together, the centrins are multifunctional proteins that
are critical to normal cellular function.
In contrast to CETN2, not much is known about the
human CETN1. Here, we characterize the human CETN1
gene as a cancer associated gene. Furthermore, based on
its expression pattern in normal testis and tumor tissues
and its regulation by DNA hypomethylation, we identify
CETN1 as a novel member of a growing family of proteins
called Cancer/Testis Antigens (CTAs) up-regulated in
prostate cancer (PCa) and pancreatic cancer.
Results and discussion
Three separate Centrin genes, CETN1-3 have been identi-
fied in both mouse and human [13]. While CETN1 and
CETN2 show substantial identity with each other (84%),
they share only about 51% identity with CETN3. CETN3
is the closest relative to yeast CDC31 (50%) however none
of the 3 centrins can compensate for loss of CDC31 in S.
cerevisiae (not shown and [14]). CETN1 is an intron-less
gene located on chromosome 18p11 that possesses all the
sequence features of an expressed retroposon: no introns,
the open reading frame without interruptions of stop co-
dons, and the coding region flanked by a pair of direct re-
peats [15]. Moreover, like most retrogenes characterized
to date [16,17], CETN1 expression is specifically restricted
to the testis of adult male mice [15] and humans (Figure 1)Figure 1 CETN1/2/3 Expression in normal tissues of Homo sapiens. Da
micro-array data.and in the photoreceptors at the back of the eye, another
immune privileged area [18,19]. Q-PCR confirms the tar-
gets in a selection of tissues for CETN1 (Additional file 1:
Figure S1). Interestingly, in mice, while Cetn1 expression
increases dramatically in the testis during neonatal devel-
opment, expression of the X-linked Cetn2 decreases to
about half the level seen before Cetn1 is expressed. Thus,
CETN1, which appears to have originated from the X-
linked paralog CETN2 via retrotransposition, may have
a unique testis-specific function or it may be required as
part of a compensatory mechanism for the inactivation
of the X-linked CETN2 during spermatogenesis. The
very fact that CETN1 is expressed only in the testis
makes it a candidate (CTA).
The CTAs are a group of >200 genes that are expressed
primarily in the testis and also expressed during carcino-
genesis [20,21]. Since the testis are an immune privileged
organ, the body does not recognize the CTAs as “self”
which makes them excellent immunological targets. In
fact, many patients treated with chemotherapy for skin
cancer have a massive immune response causing the me-
lanocytes, which can express the MAGE CTAs, to become
attacked. This response causes a permanent diminished
color in the patient’s skin and is how CTAs were first dis-
covered in 1991 [22].
The process of cancer formation is thought to be caused
by a reawakening of primitive pathways and networks
[23]. Therefore, expression of these CTAs can be thought
of as de-differentiation of the cell back to a more embry-
onic state. This phenomenon may be responsible for the
so-called cancer stem cells (CSCs) or tumor initiating cells
which are believed to give rise to all cell types of a tumor
[24]. These cells can be isolated by flow cytometry using
their cell surface markers [25]. However, up to this point
there are no published reports on CTAs in CSCs. In fact,
during sperm differentiation, the amounts of CTAs actu-
ally increases [20].ta were generated from GeoProfiles using publicly available
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transition (EMT) is a de-differentiation process. The proc-
ess of EMT allows the cancer cells, which generally come
from epithelial cells, to become more motile and aggres-
sive. The cells invade into the extracellular matrix and
transit through the circulatory system to distant sites [26].
Once the cells reach their destination, they again differen-
tiate to better colonize the target organ (e.g. bone in PCa).
Understanding this process is critical to the successful
cancer treatment, since without metastasis, most solid
organ cancers would not be fatal [27]. As would be
expected, it was found in PCa that many CTAs do
increase in metastatic disease, however the sampling done
in expression studies is from the actual metastasis, not an
invading cell [28]. CTA expression in general also corre-
lates with advanced stages of the disease.
Paradoxically, in sperm differentiation, CTA expres-
sion is actually highest in the most differentiated cells,
the sperm cell, which has lost its ability to proliferate
[29]. It is for this reason that CTA expression is often
times actually lost in testicular cancer [30]. CETN1 ex-
pression is also lost in various testicular cancers studied
along with CETN3 expression (Figure 2). It could be
argued that reduced CTA expression is due to the cells
originating mostly from the sperm precursor cells, gono-
cytes and primordial germ cells which are present before
birth. In fact, in mice, it was shown that Cetn1/3 expres-
sion are extremely dynamic during testis development
while Cetn2 is more constant [15]. Taken together, it is
reasonable to hypothesize that CETN1 might be a CTA.
Analysis of RNA by qPCR taken from PCa samples
revealed that CETN1 was expressed 6 fold higher in
cancer than normal tissues. The difference was even
more striking in pancreatic cancer xenografts which had
25 fold higher expression than RNA taken from normal






















Figure 2 CETN1 expression is upregulated in prostate and pancreatic
cancer of the prostate (n = 37) vs normal prostate in (n = 23) samples and
pancreas (n = 5).had reduced expression of CETN1 consistent with their
origin from sperm cell precursors (Figure 2). Unfortunately,
immunohistochemistry was not possible since CETN1/
CETN2 have such high identity (84%), that commercially
available antibodies have been difficult to produce.
Cancer cell lines had very little expression of CETN1
(Figure 4). This was not surprising since previous studies
have shown that CTA expression is often greatly dimin-
ished in cancer cell lines grown in 2D conditions com-
pared to the original tissue [29]. Treatment of the cell
lines with the de-acetylase inhibitor TSA had little effect
however when 5’AZA-2’Deoxycytidine (AZA) was used
on its own or with TSA there was a dramatic increase in
CETN1 expression. This suggests that promoter methy-
lation may cause downregulation of CETN1 expression
in cells lines. Whether promoter methylation is the mech-
anism used to suppress CTA expression in normal tissues
is unknown, however most CTAs respond to AZA treat-
ment [31,32]. It is unknown whether centrosome amplifi-
cation has any correlation with CETN1 status, however it
has not been shown that ectopic expression of CETN1,
CETN2 or CETN3 has any effect on centrosome number
in cancer cells however injection of CETN3 protein or
mRNA into 2 cell Xenopus laevis embryos was able to
prevent centrosome duplication [14,33,34].
The reason for the overexpression of CTAs in cancer is
not clear. It may be a side effect from a common transcrip-
tion factor acting on them as well as another oncogene. It
may also be that cells containing high levels of CTAs are
selected for since in some way they could contribute to
carcinogenesis. Most CTAs are hypothesized to be hub pro-
teins which can interact with many different proteins and
form networks not normally present in the cell [35]. One of
the salient features of hub proteins is the presence of intrin-
sic disorder [23]. In order to discern the disorder in the
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Figure 3 CETN1/2/3 expression in normal testis and different carcinomas of the testis in Homo sapiens. Data were generated from
GeoProfiles using publicly available micro-array data.
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implemented by FoldIndex makes a calculation based on
average net charge and average hydrophobicity of the se-
quence to make a disorder prediction, RONN uses a
neural network technique to predict whether any given
residue is likely to be ordered or disordered in the context
of the surrounding amino acid sequence. Although the
physical properties of amino acids are the fundamental
basis for predicting disorder, the neural network avoids
explicit parameterization of amino acids in such a manner.
Instead it uses non-gapped sequence alignment to meas-
ure ‘distances’ between windows of sequence for the
unknown protein and windowed sequences for known
folded proteins derived from the Protein Database (PDB).
Therefore, the two algorithms represent fundamentally
different approaches to disorder prediction; while both

























































































































Figure 4 The q-PCR of CETN1 after 5’Aza deoxycytidine and/or Tricho
Cells, BPH1 (Benign Prostate), CWR22 (Prostate Cancer), DU145 (Prostate Caperform well when compared to some of the other dis-
order prediction methods. However, FoldIndex performs
particularly well for fully ordered or fully disordered se-
quences, while RONN is more successful in identifying
partially disordered sequences. As shown in (Additional
file 2: Figure S2 and Additional file 3: Figure S3), the pre-
dictions by both FoldIndex and RONN are quite consist-
ent and suggest that the 3 human Centrins as well as the
yeast homolog CDC31 are indeed intrinsically disordered
proteins. However, these bioinformatic predictions need
to be experimentally confirmed. Interestingly, Salisbury
and coworkers were unable to crystallize CETN2 in the
absence of one of its binding partners, XPC [8].
From this work, it appears plausible that CETN1 is a
CTA with expression in prostate and pancreatic cancers.
Normal expression in the testis is silenced during various
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statin-A treatment. Cell lines used: PrEC (normal Prostate Epithelial
ncer), PrSC (Prostate Stroma), SW480 (Colon Cancer).
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methylation and it acts as a hub protein in cancer espe-
cially given its disordered regions.
Conclusions
CETN1 is upregulated in prostate and pancreatic cancers.
Its status as an IDP and its down-regulation in testicular
cancer further suggest it to be a member of the CTAs.
Like most CTAs, it is expressed highly in cancer, but less
so in cancer cell lines.
Methods
GEO profile data
Using a GEO profile, CETN1-3 mRNA expression levels
in normal tissues were evaluated for a wide variety of
organs [38]. The data are processed by log 2 median-
centered intensity. The arrays were done in triplicate for
standard deviations.
In addition, CETN1 mRNA expression levels of various
testicular cancers were also evaluated from a published
article [39]. Standard deviations were generated by average
of each subgroup: n = 6 normal, n = 9 Yolk Sac Tumors,
n = 12 Seminomas, n = 41 Germ Cell Tumors, n = 15 Em-
bryonal Carcinomas and n = 14 Teratomas respectively.
Patient tissue samples
This study complies with the Declaration of Helsinki
and was approved by the Johns Hopkins institutional
review board. Written informed consent was obtained
from all patients. RNA samples isolated from adult nor-
mal tissues were purchased from Origene. Tissues from
Pancreatic Xenografts were obtained from patients at
Johns Hopkins Hospital by Anirban Maitra.
Quantitative polymerase chain reaction (q-PCR)
Total RNA from normal tissues was purchased from
Origene. Prostate cancer samples were obtained from
rapid autopsies [28] and prostate cancer xenografts [40]
while pancreatic xenografts were from Dr. Anirban
Maitra (Johns Hopkins). Total mRNA were isolated
from tissues with an RNeasy kit (Qiagen) [41]. TATAA-
box binding protein (TBP) was used as a reference gene
for real-time PCR.Primers with sequences are listed in
the Additional file 4: Table S1. The amount and quality
of RNA were assessed using NanoDrop (NanoDrop) and
an Agilent 2100 Bioanalyzer. The cDNA synthesis was
performed using an iScript cDNA synthesis kit (Bio-Rad).
cDNA products were diluted 5 fold with DEPC (diethyl-
pyrocarbonate) treated water before use. The iQ SYBR
Green Supermix (Bio-Rad) was used in conjunction with
the q-PCR in Thermal Cycler C1000 (Bio-Rad). The PCR
reaction was performed with 0.2 ml of cDNA template in
25 ml of reaction mixture containing 12.5 ml of iQ SYBR
Green Supermix (Bio-Rad) and 0.25 mmol/L each primer.PCR reaction was subjected to hot start at 95°C for 3 min
followed by 45 cycles of denaturation at 95°C for 10 sec,
annealingat 60°C for 30 sec, and extension at 72°C for
30 sec. Analysis and fold differences were determined
using the comparative CT method. Fold change was cal-
culated from the ΔΔCT values with the formula, 2-ΔΔCT.
Cell culture
PCa cancer cell lines raised at 37°C under routine condi-
tions in RPMI (Invitrogen) media added with 10% fetal
bovine serum (FBS) in 5% carbon dioxide and humidified
air [42,43]. Normal prostate epithelial cells were cultured
in Prostate Epithelial Cell Basal Medium (PrEGM, Lonza)
added with BulletKit (Lonza).
5-AZA-2’-deoxycytidine and trichostatin-A treatments
Cells were plated in 10 cm dishes at a concentration den-
sity of 10^6/dish. Cells were treated with 3 μmoles/L of 5
aza 2’ deoxycytidine (Sigma Aldrich) dissolved in DMSO
for 72 hrs. Media was changed every 24 hrs with 3
μmoles/L of 5 aza 2’ deoxycytidine. Trichostatin A (Sigma
Aldrich) also dissolved in DMSO was added at a concen-
tration of 300 nmoles/L in the last 24 hrs of treatment.
After 72 hrs, Cells were washed with 1X PBS twice and
cells were harvested for RNA extraction. RNA extraction
was carried out using RNeasy kit (Qiagen). RNA concen-
tration was quantified by Nanodrop spectrophotometer.
Yeast studies
CDC31, CETN1, GFP-CETN1, CETN2 or GFP-CETN2
were all successfully expressed in Saccharomyces cerevisiae
using a vector that allows the yeast cells to become resist-
ant to histidine deficiency. The CDC31 gene was then
knocked out using a NAT cassette but only from cells
expressing ectopic CDC31, not from the human CETN ho-
mologs which failed to complement.
Additional files
Additional file 1: Figure S1. The q-PCR of various normal tissues was
performed with primers specific for CETN1/2/3. Levels of CETN were
normalized first to TBP then so that testis is equal to 1.
Additional file 2: Figure S2. FoldIndex predicts that CETN1, CETN2,
CETN3 and CDC31 are all IDPs. The ordered regions are depicted in
green and the disordered regions are shown in red. http://bip.weizmann.
ac.il/fldbin/findex.
Additional file 3: Figure S3. RONN predicts that CETN1, CETN2, CETN3
and CDC31 are all IDPs. The percent probability of disorder is shown on
the y-axis. Regions with a probability of 0.5 or higher are predicted to be
disordered. http://www.bioinformatics.nl/~berndb/ronn.html.
Additional file 4: Table S1. A list of primers for q-PCR.
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